<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11862045</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.1509</article-id><article-id pub-id-type="other">EPV0909</article-id><article-id pub-id-type="pii">S0924933824015098</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Viewing</subject></subj-group></article-categories><title-group><article-title>Patient satisfaction with 6-month paliperidone palmitate versus other long-acting injectable antipsychotics</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>P&#x000e9;rez-Balaguer</surname><given-names>A.</given-names></name><xref rid="aff3305" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1358" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Garc&#x000ed;a del Castillo</surname><given-names>I.</given-names></name><xref rid="aff3305" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>G&#x000f3;mez-Esteban</surname><given-names>B.</given-names></name><xref rid="aff3305" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Vicente-Burguillo</surname><given-names>M.</given-names></name><xref rid="aff3305" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Vizca&#x000ed;no-Herrezuelo</surname><given-names>H.</given-names></name><xref rid="aff3306" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Castelao-Almod&#x000f3;var</surname><given-names>S.</given-names></name><xref rid="aff3306" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Arce de la Riva</surname><given-names>A.</given-names></name><xref rid="aff3306" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Neira-Serrano</surname><given-names>F.</given-names></name><xref rid="aff3307" ref-type="aff">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="aff3305"><sup>1</sup>Psychiatry, <institution>El Escorial Hospital</institution></aff><aff id="aff3306"><sup>2</sup>Psychiatry, <institution>Puerta de Hierro University Hospital</institution></aff><aff id="aff3307"><sup>3</sup>Statistics, <institution>Francisco de Vitoria University</institution>, <city>Madrid</city>, <country>Spain</country></aff><author-notes><corresp id="cor1358"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="1484">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S726</fpage><lpage>S726</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824015098a.pdf"/><abstract><sec id="sec8164"><title>Introduction</title><p>Long-acting injectable antipsychotics (LAIs) offer advantages for schizophrenic patients compared to oral antipsychotics: less frequent dosing, lower relapse rates, better adherence, and lower healthcare costs. LAIs include paliperidone, aripiprazole, olanzapine, risperidone, and zuclopenthixol. Paliperidone palmitate is the only antipsychotic with two formulations with an administration interval longer than one month (3-monthly and 6-monthly), which could be better for the patient and help ensure treatment continuity, especially in cases of limited access to the health care system.</p></sec><sec id="sec8165"><title>Objectives</title><p>
To assess the satisfaction of patients under treatment with 6-month paliperidone palmitate compared to other long-acting injectable antipsychotics with a higher frequency of administration.</p></sec><sec id="sec8166"><title>Methods</title><p>
We analyzed the satisfaction level of a sample of patients receiving treatment with LAIs at the Mental Health Center of El Escorial. All patients had a diagnosis of schizophrenia or other psychotic disorders (according to DSM-5). Patients who met the inclusion criteria completed the Treatment Satisfaction Questionnaire for Medication (TSQM), a generic questionnaire of treatment satisfaction that measures four dimensions: side effects, treatment efficacy, comfort of use, and overall satisfaction. Other clinical and socio-demographic variables were collected, as well as the type of injectable, dose, and frequency of administration.</p></sec><sec id="sec8167"><title>Results</title><p>Data from approximately 30 patients will be analyzed and discussed later.</p></sec><sec id="sec8168"><title>Conclusions</title><p>Less frequent administration of LAIs may result in greater patient satisfaction and be just as beneficial clinically. Treatment satisfaction is positively associated with an improvement in psychotic symptoms and seems to be related to better adherence.</p></sec><sec id="sec8169"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>